Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia : A report from CYP-C
© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC..
Thromboembolism (TE) is associated with reduced survival in pediatric acute lymphoblastic leukemia (ALL). It has been hypothesized that TE might signal leukemic aggressiveness. The objective was to determine risk factors for TE during ALL induction (TEind ) therapy and whether TEind is associated with treatment refractoriness. This retrospective cohort study using the population-based Cancer in Young People Canada (CYP-C) registry included children <15 years of age diagnosed with ALL (2000-2019) and treated at one of 12 Canadian pediatric centers outside of Ontario. Univariate and multivariable logistic regression models were used to determine risk factors for TEind and whether TEind predicted induction failure and ALL treatment intensification. The impact of TEind on overall and event-free survival was estimated using Cox proportional hazard regression models. The study included 2589 children, of which 45 (1.7%) developed a TEind . Age (<1 year and ≥10 years vs. 1-<10 years), T-cell phenotype, high-risk ALL, and central nervous system involvement were all associated with TEind in univariate analysis. Age and T-cell phenotype remained independent predictors of TEind in multivariable analysis. Induction failure occurred in 53 patients (2.1%). TEind was not associated with induction failure (OR: not estimable) or treatment intensification (adjusted OR [95% CI]: 0.66 [0.26-1.69]). TEind was independently associated with overall survival (adjusted HR [95% CI]: 2.54 [1.20-5.03]) but not event-free survival (adjusted HR [95% CI] 1.86 [0.98-3.51]). In this population-based study of children treated with contemporary chemotherapy protocols, TEind was associated with age and T-cell phenotype and mortality but did not predict induction failure.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
---|---|
Enthalten in: |
American journal of hematology - 99(2024), 2 vom: 22. Jan., Seite 274-283 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Pelland-Marcotte, Marie-Claude [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/ajh.27171 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM366556177 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM366556177 | ||
003 | DE-627 | ||
005 | 20240122232025.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240108s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/ajh.27171 |2 doi | |
028 | 5 | 2 | |a pubmed24n1267.xml |
035 | |a (DE-627)NLM366556177 | ||
035 | |a (NLM)38164978 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Pelland-Marcotte, Marie-Claude |e verfasserin |4 aut | |
245 | 1 | 0 | |a Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia |b A report from CYP-C |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.01.2024 | ||
500 | |a Date Revised 22.01.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. | ||
520 | |a Thromboembolism (TE) is associated with reduced survival in pediatric acute lymphoblastic leukemia (ALL). It has been hypothesized that TE might signal leukemic aggressiveness. The objective was to determine risk factors for TE during ALL induction (TEind ) therapy and whether TEind is associated with treatment refractoriness. This retrospective cohort study using the population-based Cancer in Young People Canada (CYP-C) registry included children <15 years of age diagnosed with ALL (2000-2019) and treated at one of 12 Canadian pediatric centers outside of Ontario. Univariate and multivariable logistic regression models were used to determine risk factors for TEind and whether TEind predicted induction failure and ALL treatment intensification. The impact of TEind on overall and event-free survival was estimated using Cox proportional hazard regression models. The study included 2589 children, of which 45 (1.7%) developed a TEind . Age (<1 year and ≥10 years vs. 1-<10 years), T-cell phenotype, high-risk ALL, and central nervous system involvement were all associated with TEind in univariate analysis. Age and T-cell phenotype remained independent predictors of TEind in multivariable analysis. Induction failure occurred in 53 patients (2.1%). TEind was not associated with induction failure (OR: not estimable) or treatment intensification (adjusted OR [95% CI]: 0.66 [0.26-1.69]). TEind was independently associated with overall survival (adjusted HR [95% CI]: 2.54 [1.20-5.03]) but not event-free survival (adjusted HR [95% CI] 1.86 [0.98-3.51]). In this population-based study of children treated with contemporary chemotherapy protocols, TEind was associated with age and T-cell phenotype and mortality but did not predict induction failure | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Kulkarni, Ketan |e verfasserin |4 aut | |
700 | 1 | |a Tran, Thai Hoa |e verfasserin |4 aut | |
700 | 1 | |a Stammers, David |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Sumit |e verfasserin |4 aut | |
700 | 1 | |a Sung, Lillian |e verfasserin |4 aut | |
700 | 1 | |a Athale, Uma H |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d 1993 |g 99(2024), 2 vom: 22. Jan., Seite 274-283 |w (DE-627)NLM000124354 |x 1096-8652 |7 nnns |
773 | 1 | 8 | |g volume:99 |g year:2024 |g number:2 |g day:22 |g month:01 |g pages:274-283 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/ajh.27171 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 99 |j 2024 |e 2 |b 22 |c 01 |h 274-283 |